{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:10:38Z","timestamp":1783095038656,"version":"3.54.6"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.berh.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T07:16:03Z","timestamp":1477984563000},"page":"304-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Advancements in the management of uveitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Sergio","family":"Schwartzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of uveitis study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"issue":"5\u20136","key":"10.1016\/j.berh.2016.07.005_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/eye.2015.269","article-title":"Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up","volume":"30","author":"Groen","year":"2016","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.survophthal.2011.05.003","article-title":"Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease","volume":"56","author":"Durrani","year":"2011","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib6","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0161-6420(01)00576-0","article-title":"Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients","volume":"108","author":"Samson","year":"2001","journal-title":"Ophthalmology"},{"issue":"5 Suppl. 61","key":"10.1016\/j.berh.2016.07.005_bib7","first-page":"S145","article-title":"Use of methotrexate in patients with uveitis","volume":"28","author":"Ali","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2016.07.005_bib8","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2016.07.005_bib9","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/09273940903137675","article-title":"Mycophenolate sodium for immunosuppressive treatment in uveitis","volume":"17","author":"Deuter","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.berh.2016.07.005_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000336192","article-title":"Mycophenolate mofetil use in the treatment of noninfectious uveitis","volume":"51","author":"Klisovic","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib12","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ophtha.2005.02.020","article-title":"Mycophenolate mofetil therapy for inflammatory eye disease","volume":"112","author":"Thorne","year":"2005","journal-title":"Ophthalmology"},{"issue":"2\u20133","key":"10.1016\/j.berh.2016.07.005_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9394(14)77814-6","article-title":"Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents","volume":"96","author":"Nussenblatt","year":"1983","journal-title":"Am J Ophthalmol"},{"issue":"8344","key":"10.1016\/j.berh.2016.07.005_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(83)90230-1","article-title":"Treatment of intraocular inflammatory disease with cyclosporin A","volume":"2","author":"Nussenblatt","year":"1983","journal-title":"Lancet"},{"issue":"Pt 3","key":"10.1016\/j.berh.2016.07.005_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/eye.1990.68","article-title":"Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation","volume":"4","author":"Towler","year":"1990","journal-title":"Eye"},{"issue":"8647","key":"10.1016\/j.berh.2016.07.005_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/112067210701700110","article-title":"Long-term follow-up of tacrolimus treatment in immune posterior uveitis","volume":"17","author":"Figueroa","year":"2007","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib22","first-page":"158","article-title":"Azathioprine for glucocorticoid resistant noninfectious uveitis","volume":"93","author":"Mili-Boussen","year":"2015","journal-title":"La Tunis Med"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0161-6420(01)00864-8","article-title":"Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.berh.2016.07.005_bib26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A\u00a0randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib27","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00296-003-0308-1","article-title":"Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis","volume":"23","author":"Mangge","year":"2003","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis-associated uveitis","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/ard.2006.065441","article-title":"Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease","volume":"66","author":"Sharma","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynjala","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry","volume":"40","author":"Zannin","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib35","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10384-012-0202-z","article-title":"Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis","volume":"57","author":"Matsuda","year":"2013","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3109\/09273948.2010.496914","article-title":"Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis","volume":"18","author":"Papadia","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib38","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/j.1572-0241.2008.01982_12.x","article-title":"Treatment of recurrent Crohn's uveitis with infliximab","volume":"103","author":"Ally","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","article-title":"Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab","volume":"97","author":"Fries","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Ocular Behcet's Disease Research Group of J. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.berh.2016.07.005_bib43","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A\u00a0prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib45","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","article-title":"Adalimumab therapy for childhood uveitis","volume":"149","author":"Vazquez-Cobian","year":"2006","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynjala","year":"2008","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2016.07.005_bib47","article-title":"Psoriatic uveitis responding to adalimumab therapy","author":"Turel Ermertcan","year":"2013","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","volume":"97","author":"Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcrs.2012.02.026","article-title":"Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab","volume":"38","author":"Soheilian","year":"2012","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1546-0096-11-16","article-title":"Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis","volume":"11","author":"Simonini","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/09273948.2011.623213","article-title":"Sarcoid-related uveitis occurring during adalimumab therapy","volume":"20","author":"Seve","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.berh.2016.07.005_bib53","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/kes212","article-title":"Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease\u2013a case cohort interventional study","volume":"51","author":"Sen","year":"2012","journal-title":"Rheumatol Oxf"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib54","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.005_bib55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A\u00a0randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib56","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Behcet's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273948.2011.633205","article-title":"Infliximab and adalimumab for uveitis","volume":"20","author":"Martel","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib58","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/bjo.2006.108050","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Mansour","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib59","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-013-2275-x","article-title":"Adalimumab for juvenile idiopathic arthritis-associated uveitis","volume":"251","author":"Magli","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib60","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/09273948.2010.495814","article-title":"Optic neuritis associated with adalimumab in the treatment of uveitis","volume":"18","author":"Li","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"4 Suppl. 67","key":"10.1016\/j.berh.2016.07.005_bib61","first-page":"S93","article-title":"Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet's disease to infliximab","volume":"29","author":"Leccese","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2016.07.005_bib62","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OPTH.S23646","article-title":"Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"5","author":"Kotaniemi","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.berh.2016.07.005_bib63","doi-asserted-by":"crossref","first-page":"560632","DOI":"10.1155\/2013\/560632","article-title":"Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis","volume":"2013","author":"Garcia-De-Vicuna","year":"2013","journal-title":"Mediat Inflamm"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib64","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","article-title":"A\u00a0three-centre experience with adalimumab for the treatment of non-infectious uveitis","volume":"97","author":"Dobner","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib66","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"Diaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Diaz-Llopis","year":"2008","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/09273948.2013.770888","article-title":"Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses","volume":"21","author":"Cordero-Coma","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Callejas-Rubio","year":"2008","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib70","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/eye.2011.320","volume":"26","author":"Calleja","year":"2012","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib71","first-page":"456","article-title":"Adalimumab therapy for refractory childhood uveitis","volume":"17","author":"Bravo-Ljubetic","year":"2013","journal-title":"J\u00a0AAPOS"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib73","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema","volume":"117","author":"Androudi","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.berh.2016.07.005_bib74","article-title":"Long-term treatment with golimumab for severe uveitis","author":"Miserocchi","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib75","first-page":"320","article-title":"Golimumab treatment for complicated uveitis","volume":"31","author":"Miserocchi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib76","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib77","first-page":"175","article-title":"Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. Journal of clinical rheumatology","volume":"7","author":"Smith","year":"2001","journal-title":"Pract Rep Rheumatic Musculoskelet Dis"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib78","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib79","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatol Oxf"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A\u00a0randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2016.07.005_bib81","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib82","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2016.07.005_bib83","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.07.005_bib84","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","author":"Levy-Clarke","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.berh.2016.07.005_bib86","doi-asserted-by":"crossref","first-page":"1892 e3-4","DOI":"10.1016\/j.ophtha.2011.05.019","article-title":"Golimumab for uveitis","volume":"118","author":"Cordero-Coma","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.berh.2016.07.005_bib87","article-title":"Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series","author":"Faez","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Behcet disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","article-title":"Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"William","year":"2012","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"issue":"13","key":"10.1016\/j.berh.2016.07.005_bib90","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.berh.2016.07.005_bib91","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0896-8411(03)00113-6","article-title":"Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration","volume":"21","author":"Nussenblatt","year":"2003","journal-title":"J\u00a0Autoimmun"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2008.05.001","article-title":"High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis","volume":"31","author":"Yeh","year":"2008","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib93","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","article-title":"Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series","volume":"112","author":"Nussenblatt","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib94","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcjo.2011.06.008","article-title":"Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease","volume":"46","author":"Wroblewski","year":"2011","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib95","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib96","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3121\/cmr.4.4.294","article-title":"Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?","volume":"4","author":"Ooi","year":"2006","journal-title":"Clin Med Res"},{"issue":"3 Suppl. 77","key":"10.1016\/j.berh.2016.07.005_bib97","first-page":"152","article-title":"Anakinra for resistant Behcet uveitis: why not?","volume":"31","author":"Emmi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib98","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","article-title":"Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome","volume":"91","author":"Teoh","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.berh.2016.07.005_bib99","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"Gul","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1076\/ocii.7.2.75.4017","article-title":"Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis","volume":"7","author":"Petrinovic-Doresic","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.berh.2016.07.005_bib101","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib102","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2016.07.005_bib103","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Adan","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und Exp Ophthalmol"},{"key":"10.1016\/j.berh.2016.07.005_bib104","article-title":"Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient","author":"Tsang","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.berh.2016.07.005_bib105","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Behcet uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefe's Archive Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.berh.2016.07.005_bib106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","article-title":"Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis","volume":"144","author":"Plskova","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.berh.2016.07.005_bib107","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res Hob"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","article-title":"Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis","volume":"249","author":"Kenawy","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.berh.2016.07.005_bib109","first-page":"1897","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report","volume":"35","author":"Angeles-Han","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2016.07.005_bib110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.20359","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et\u00a0al","volume":"63","author":"Elhai","year":"2011","journal-title":"Arthritis Care Res Hob"},{"issue":"10","key":"10.1016\/j.berh.2016.07.005_bib111","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ophtha.2008.03.027","article-title":"Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis","volume":"115","author":"Parikh","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.berh.2016.07.005_bib112","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","article-title":"Rituximab for noninfectious uveitis","volume":"51","author":"Miserocchi","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"8","key":"10.1016\/j.berh.2016.07.005_bib113","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatol Oxf"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2016.07.005_bib114","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/annrheumdis-2016-eular.1266","article-title":"Quiescence in active and inactive non-infectious, intermediate, posterior, or panuveitis in patients treated with adalimumab: visual I and visual II trials","volume":"75","author":"Landewe","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:57:55Z","timestamp":1749682675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694216300523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1521694216300523"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2016.07.005","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in the management of uveitis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}